From making major deals to advancing future innovators, here are three Houston leaders to know this week. Courtesy photos

This week's movers and shakers in Houston innovation are dealmakers and leaders — from securing huge partnerships to influencing the next generation of inventors. These are the three innovators to know in Houston this week.

Rakesh Agrawal, CEO of SnapStream

Courtesy of SnapStream

A Houston tech innovator just made a deal with Verizon. Verizon Digital Media Services announced that SnapStream is the "official transition partner" for a product under Volicon Observer, a company that was acquired by Verizon in 2016. SnapStream's CEO Rakesh Agrawal says in a release that the two entities have similar products, features, and even customers, but have always had a respectful relationship.

"SnapStream is known, among other things, for the great support we provide, and we look forward to providing the same high-quality support to Volicon customers," Agrawal says in the release. "We hope to eventually earn the business of current Volicon customers by converting them into SnapStream customers." Read the full story here.

Enrico Ladendorf, founder and managing partner of Pason Power

Courtesy of Pason Power

Another Houston dealmaker is Enrico Ladendorf, founder and managing partner of Pason Power. In layman's terms, Pason Power offers an array of technologies — including AI, IoT, real-time automation — that support energy storage systems throughout a project's lifecycle. Energy storage systems is a wide umbrella that includes everything from the massive systems used to store renewable energy and biofuels, to household batteries, which store electricity.

"We have intelligent energy management system, which is an intelligent brain that sits inside an energy storage system," says Ladendorf. "We have this intelligent, fully-autonomous system that knows the physical operation of (energy storage and drill rigs), and it makes it brain-dead simple." Read the full story here.

Pam Rosen, general manager of the Shell Eco-marathon

Courtesy of Shell

Houstonian Pam Rosen lead Shell's Eco-marathon, which took place from April 3 to 6. Two student teams represented Houston in the competition — one from Rice University and James E. Taylor High School.

"We really needed to get more young people interested in technology careers," says Pam Rosen, general manager of the Shell Eco-marathon. "It [doesn't] even need to be with Shell. It's more about the method, science, and helping [students[ gravitate toward those opportunities." Read the full story here.

Two Houston student teams are competing in Shell's international competition. Courtesy of Shell

2 Houston student teams to compete in Shell’s international eco-friendly driving challenge

Off to the races

What started as a bet in the '30s has evolved into the Shell's Eco-marathon. The competition challenges high school and college students to engineer the fuel-efficient vehicles. And at this year's Shell Eco-marathon Americas, two teams will be representing Houston.

Students from Rice University and James E. Taylor High School are competing in the Shell Eco-marathon Americas, which begins April 3 and wraps up April 6. This year's competition is being held at Sonoma Raceway in Sonoma, California, and will include more than 90 teams from high schools and colleges throughout North and South America.

That's a far cry from the competition's origins. Shell's first fuel efficiency competition took place in 1939, when two Illinois scientists struck a friendly bet over who could engineer a vehicle that ran the furthest on a gallon of gas. The company held an employee competition that year and, save for around a decade and a half in the '70s and '80s, the competition has been held in some capacity every year.

"We really needed to get more young people interested in technology careers," says Pam Rosen, general manager of the Shell Eco-marathon. "It [doesn't] even need to be with Shell. It's more about the method, science, and helping [students[ gravitate toward those opportunities."

The Shell Eco-marathon has adapted with the decades. Students design vehicles that run on gas, diesel, and biofuels, as well as batteries and electricity. Vehicles fueled by GTL (gas-to-liquid) and hydrogen have also competed in the Eco-marathon, Rosen says.

"It kind of ebbs and flows toward what we see the automotive manufacturers trending toward," Rosen says.

The teams from Rice University is a returning presence to the Eco-marathon, while the team from James E. Taylor High School is competing in the Eco-marathon for its first time. Both teams engineered battery-powered electric urban concept vehicles, Rosen says, and describes "urban concept vehicles" as being similar to Smart cars.

The team that takes the top prize in the Americas' urban concept vehicle competition will compete in the Eco-marathon's regional qualifiers in London. As for the lucky winner? They'll head to Italy, where they'll get to drive their vehicle on the racetrack used in the San Marino Grand Prix in Marino, Italy, Rosen says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”